As an expert in drug imports, we enable doctors, pharmacies and clinics to legally access unlicensed drugs – reliably, transparently and in accordance with § 73.3 of the German Medicines Act (AMG).
Innovative therapies, shortages, rare diseases or expired drug approvals – they all often have one thing in common: they require named patient access.
73.3 of the German Medicines Act (AMG) provides the legal basis for this and enables doctors, pharmacies and clinics to continue to provide patients with fast and safe care.
Hope for patients: access to modern, adequate and often life-saving therapy
Self-determination & care: patients receive treatment options that they did not have before
Our mission: Patient first! Fast access can save lives
In order for named patient pathways under Section § 73.3 (AMG) to be lawful, three conditions must be met:
We review each request individually and assist doctors and pharmacies in ensuring correct processing.
Thanks to our international network, we source medicines worldwide – quickly, safely and transparently.
We support public pharmacies, hospital pharmacies and clinics alike – including documentation and billing (DRG/NUB in the clinic sector).
We combine the legal requirements with clear processes, international sourcing and GDP-compliant logistics. This ensures that every named patient pathway is 100% compliant and reliably implemented.
There are various forms of import in the pharmaceutical trade – but they differ significantly in purpose and significance:
Individual patient care with medicines that are not approved or currently unavailable in Germany. Medically prescribed, strictly regulated and always patient-oriented.
Trade model for medicines already approved in the EU. The focus is on price and competitive advantages, not on individual care.
Re-import of medicines approved in Germany that are brought back from abroad at a lower price. Also economically oriented.
While parallel and re-imports serve trade and price advantages, named patient pathways focus on medical necessity and patient care.
Feature
Approval in Germany
Purpose
Medical prescription required
Official approval
Individual patient care
Legal framework
Focus
Risk for doctor/pharmacy
Named patient pathway (§ 73.3 AMG)
Not approved, only possible under § 73.3 AMG
Patient care in cases of medical emergency
Mandatory
Individual approval required
Always individualised for each patient
§ 73.3 AMG
Patient care / medical necessity
Legally compliant if handled correctly
Parallel import
Already approved EU medicine
Economic trade (price advantages)
Not necessary
No individual approval
No
EU internal market regulations
Trade / pricing
Low
Re-import
Already approved in Germany
Price advantages through re-import to the country of origin
Not necessary
No individual approval
No
EU internal market regulations
Trade / pricing
Low
To enable you to treat your patients safely and quickly, we support you in researching and sourcing named patient pathways.
Your advantage:
One contact person, one consistent process, full transparency.
Drug Request
Extensive research
Regulatory review under § 73.3 AMG
Global product sourcing
Customs & documentation
Quality & compliance management
GDP-compliant delivery within Germany
Over 60 years of experience in international pharmaceutical imports
Supplying pharmacies, clinics, and wholesalers throughout the DACH region
Own WDA-licensed and GDP-compliant warehouse network
International supply chains in over 50 countries
Specialized team for customs, national regulations and documentation
We combine global reach with local compliance.
Contact us now for a fast, secure and legally compliant solution.
TOLL-free HOTLINE 0800 678 7243
+49 40 248 357 0
Kiebitzhörn 5-9
22885 Barsbüttel
Germany